Lixisenatide
Also referenced as: Adlyxin, Soliqua component
An exendin-derived GLP-1 receptor agonist with standalone and combination-product history.
- Evidence grade
- AStrong Clinical Evidence
Strong Clinical Evidence
- Regulatory status
- FDA Approved for Specific Indication
Adlyxin was FDA-approved for adult type 2 diabetes but the standalone US product was discontinued. Lixisenatide remains a component of FDA-approved Soliqua with insulin glargine.
- Human data
- Yes
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
An exendin-derived GLP-1 receptor agonist with standalone and combination-product history.
Adlyxin was FDA-approved for adult type 2 diabetes but the standalone US product was discontinued. Lixisenatide remains a component of FDA-approved Soliqua with insulin glargine.
The discontinued standalone US product and current combination product are not equivalent formulations.
Why It's Being Studied
- Type 2 diabetes
- Post-meal glucose signalling
Mechanism of Action
GLP-1 receptor activation influences glucose-dependent insulin secretion and gastric emptying.
GLP-1 receptor activation influences glucose-dependent insulin secretion and gastric emptying. The discontinued standalone US product and current combination product are not equivalent formulations.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Type 2 diabetes
- Post-meal glucose signalling
- Subcutaneous approved formulations
Evidence Summary
Human diabetes trials support product-specific glycemic benefits; combination studies also include insulin glargine.
Higher tiers carry more weight. Filled tiers have evidence for Lixisenatide; tap to read it.
- Human diabetes trials support product-specific glycemic benefits; combination studies also include insulin glargine.
2 cited sources.
- Prescribing label2
Human clinical evidence
- Human diabetes trials support product-specific glycemic benefits; combination studies also include insulin glargine.
Reported Adverse Events in Research
- Gastrointestinal intolerance, pancreatitis and dehydration-related kidney injury are concerns; combination products add insulin-related hypoglycemia.
Limitations of Current Evidence
- The discontinued standalone US product and current combination product are not equivalent formulations.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Lixisenatide | Trofinetide | |
|---|---|---|
| Evidence grade | A — Strong Clinical Evidence | B — Moderate Human Evidence |
| Regulatory status | FDA Approved for Specific Indication | FDA Approved for Specific Indication |
| Human data | Yes | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Subcutaneous approved formulations | Oral approved medicine |
| Cited sources | 2 | 2 |
Frequently Asked Questions
Research References
- Prescribing label
Lixisenatide — prescribing label
- Prescribing label
SOLIQUA prescribing sources